CD8A and neoplasm: Our observation that blocking PPARα restored DCs immune function in vitro prompted us to examine whether PPARα blockade decreased the lipid content of TIDCs or altered the ability of TIDCs to prime CD8+ T cells and promote anti-tumor immunity.